Nucelion partners with VeGen Bio on CAR-T therapy for multiple myeloma
The story in brief
Nucelion Therapeutics, Bharat Biotech's subsidiary, has partnered with VeGen Bio to manufacture CAR-T therapy VL-2511 in India. The collaboration aims to reduce treatment costs and improve patient access by streamlining production and optimising economics. This partnership will serve as the exclusive manufacturing partner for VeGen's lead candidate, a Phase II clinical-stage dual BCMA/CD19 therapy.